GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (FRA:DYF1) » Definitions » Issuance of Debt

Dynavax Technologies (FRA:DYF1) Issuance of Debt : €0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Issuance of Debt?

Dynavax Technologies's Issuance of Debt for the three months ended in Mar. 2024 was €0.0 Mil.

Dynavax Technologies's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

Dynavax Technologies Issuance of Debt Historical Data

The historical data trend for Dynavax Technologies's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Issuance of Debt Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.83 - 194.54 - -

Dynavax Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Dynavax Technologies Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dynavax Technologies Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (FRA:DYF1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (FRA:DYF1) » Definitions » Issuance of Debt
Comparable Companies
SUPN AVDL TLRY PCRX TARO ANIP COLL AMRX IRWD AMPH XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
DVAX:USA DYF1:Germany
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Website
https://www.dynavax.com
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (FRA:DYF1) Headlines

No Headlines